Sugi Predict

Sugi Predict / Compounds / SCHEMBL3933935

SCHEMBL3933935

SCHEMBL3933935

CN1CCN(CC(=O)N(C)c2ccc(N/C(=C3\C(=O)Nc4cc(Cl)ccc43)c3ccc4cccnc4c3)cc2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AAK1 Q2M2I8 1/20 0.41
▸ ABL1 P00519 3/20 0.37
▸ PDGFRB P09619 2/20 0.37
▸ KIT P10721 2/20 0.37
▸ FGFR1 P11362 2/20 0.37
▸ PDGFRA P16234 2/20 0.37
▸ FLT1 P17948 2/20 0.37
▸ FLT4 P35916 2/20 0.37
▸ KDR P35968 2/20 0.37
▸ NTRK1 P04629 1/20 0.37
▸ CSF1R P07333 1/20 0.37
▸ RET P07949 1/20 0.37
▸ FGFR2 P21802 1/20 0.37
▸ FGFR4 P22455 1/20 0.37
▸ FGFR3 P22607 1/20 0.37
▸ NTRK3 Q16288 1/20 0.37
▸ SRC P12931 3/20 0.36
▸ PLK1 P53350 2/20 0.36
▸ LMNA P02545 2/20 0.35
▸ USP2 O75604 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5859784 1.00 AAK1 (0.41) AAK1ABL1PDGFRBKITFGFR1
SCHEMBL5859729 0.95 AAK1 (0.41) AAK1ABL1PDGFRBKITFGFR1
SCHEMBL3933290 0.95 AAK1 (0.41) AAK1ABL1PDGFRBKITFGFR1
SCHEMBL3935551 0.92 AAK1 (0.41) AAK1ABL1PDGFRBKITFGFR1
SCHEMBL3935565 0.92 AAK1 (0.41) AAK1ABL1PDGFRBKITFGFR1
SCHEMBL226540 0.88 AAK1 (0.44) AAK1ABL1PDGFRBKITFGFR1
SCHEMBL226539 0.88 AAK1 (0.44) AAK1ABL1PDGFRBKITFGFR1
SCHEMBL3933830 0.87 GPR55 (0.36) PLK1
SCHEMBL5859706 0.87 GPR55 (0.36) PLK1
SCHEMBL5856857 0.87 PLK1 (0.46) ABL1KITKDRNTRK1CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1551830-B1 HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBATORS BOEHRINGER INGELHEIM PHARMA (DE) 2009-04-08 — — EP disclosed
US-7148249-B2 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-12-12 — — US disclosed
EP-1551830-A2 HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBATORS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-07-13 — — EP disclosed
US-20050054710-A1 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-03-10 — — US disclosed
WO-2004026829-A2 HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBITORS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-04-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054710-A1 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments CDK1, CDK2, CDK3 AAK1 1459/4885ABL1 112/4885PDGFRB 609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.